Filed with ASX · · 12 pages · English
Racura reported a strong cash balance at the end of the quarter, with a substantial portion of expenditures directed towards research and development activities. The company continues to progress its clinical programs and has received ethics approvals for additional trial sites, supporting its ongoing research efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement September 2026 Quarterly Activities Report & Appendix 4C ? First patient safely treated with RC220 & osimertinib in the HARNESS-1 trial for patients with EGFR-mutated non-small cell lung cancer ? Phase 1 CPACS trial expands to South Korea, allowing for accelerated patient...
